Pharmacoeconomic Evaluation of Anti-VEGF Drugs and Laser Photocoagulation for The Treatment of DME in China
LIU Jia1,2, JIANG Ya-wen3, NI Wei-yi2, HE Xiao-ning1,2*
1. School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China; 2. Medicine Policy and Economics Research Center of School of Pharmaceutical Science and Technology of Tianjin University, Tianjin 300072, China; 3. School of Public Health, Sun Yat-sen University, Shenzhen 510006, China
Abstract：OBJECTIVE To evaluate the cost-effectiveness of ranibizumab and aflibercept compared with laser photocoagulation for the treatment of diabetic macular edema (DME) from Chinese societal perspective. METHODS A Markov model was constructed to simulate the long-term outcomes and costs of treating DME. Transition probabilities were calculated from the raw data of randomized controlled trial and published network Meta-analysis. Health state utilities were estimated through literature, and costs were estimated from experts consultation of 6 hospitals in China and published literature. The primary outcomes of the model were costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER). Uncertainty was addressed via univariate and probabilistic sensitivity analyses. RESULTS The ICER comparing ranibizumab with laser photocoagulation was ￥61 174·QALY-1, comparing aflibercept with laser photocoagulation was ￥138 232·QALY-1. Based on the generally accepted ICER threshold of 3 times per-capita GDP (￥59 660, 2017 China), ranibizumab and aflibercept were found to be cost-effective compared with laser photocoagulation. Comparing ranibizumab with aflibercept, ranibizumab was the dominant therapy, with an incremental gain of 0.03 QALYs and cost savings of ￥22 053. Univariate and probabilistic sensitivity analysis demonstrated the robustness of the results. CONCLUSION Compared with laser photocoagulation, ranibizumab and aflibercept are the cost-effective treatment for DME; compared with aflibercept, ranibizumab is the dominant treatment for DME.
刘佳, 蒋亚文, 倪惟一, 贺小宁. 抗VEGF类药物与传统激光疗法用于治疗糖尿病性黄斑水肿的药物经济学评价[J]. 中国药学杂志, 2020, 55(5): 402-407.
LIU Jia, JIANG Ya-wen, NI Wei-yi, HE Xiao-ning. Pharmacoeconomic Evaluation of Anti-VEGF Drugs and Laser Photocoagulation for The Treatment of DME in China. Chinese Pharmaceutical Journal, 2020, 55(5): 402-407.
Chinese Diabetes Society. Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 edition)[J]. Chin J Pract Intern Med (中国实用内科杂志), 2018, 38(4):292-344.
[2]
YANG W, LU J, WENG J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362(12):1090-1101.
[3]
GUNDOGAN F C, YOLCU U, AKAY F, et al. Diabetic macular edema[J]. Pak J Med Sci, 2016, 32(2):505-510.
[4]
HONG T P, YANG J. Transformational medical research on diabetes prevention and treatment in China:opportunities and challenges[J]. Chin J Diabet Mell(中华糖尿病杂志), 2017, 9(12):729-731.
[5]
STEPHEN G S, INGRID U S, MICHAEL W S, et al. Update on corticosteroids for diabetic macular edema[J]. Clin Ophthalmol, 2016,(10):1723-1730.
[6]
ERCALIK N Y, IMAMOQLU S, KUMRAL E T, et al. Influence of the epiretinal membrane on ranibizumab therapy outcomes in patients with diabetic macular edema[J]. Arq Bras Oftalmol, 2016, 79(6):373-375.
[7]
MITCHELL P, BANDELLO F, SCHMIDT-ERFURTH U, et al. The RESTORE study:ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4):615-625.
[8]
SCHMIDT-ERFURTH U, LANG G E, HOLZ F G, et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema:the RESTORE extension study[J]. Ophthalmology, 2014, 121(5):1045-1053.
[9]
KOROBELNIK J F, DO D V, SCHMIDT-ERFURTH U, et al. Intravitreal aflibercept for diabetic macular edema[J]. Ophthalmology, 2014,121(11):2247-2254.
[10]
HEIER J S, KOROBELNIK J F, BROWN D M, et al. Intravitreal aflibercept for diabetic macular edema:148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11):2376-2385.
[11]
PAUL M, LIEVEN A. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema(DME) causing visual impairment:evidence from the RESTORE trial[J]. Br J Ophthalmol, 2012, 96(5):688-693.
[12]
STEPHANE A RGNIER, MALCOLM W, HAIG J, et al. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema:a UK healthcare perspective[J]. Clinicoecon Outcomes Res, 2015,6(7):235-247.
[13]
LIU G E. Guidelines and Guidelines for the Evaluation of Pharmacoeconomics in China:2015 Edition (中国药物经济学评价指南及导读:2015年版) [M]. Beijing:Science Press, 2015.
[14]
REGNIER S, MALCOLM W, ALLEN F, et al. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema:a systematic review and network Meta-analysis[J]. PLoS One, 2014, 9(7):e102309.
[15]
BRAGG F, HOLMES M V, IONA A, et al. Association between diabetes and cause-specific mortality in rural and urban areas of China[J]. JAMA, 2017, 317(3):280-289.
[16]
HIRAI F E, KNUDTSON M D, KLEIN B E, et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes[J]. Am J Ophthalmol, 2008, 145(4):700-706.
[17]
WHO. Global Health Observatory data repository, Life tables by country, China[EB/OL]. [2018-04-20] http://apps.who.int/gho/data/view.main.60340?lang=en.
[18]
XIAO D G, FANG H L, LI J W, et al. Burden of low vision and blindness in Chinese elder population:data from field survey[J]. Value Health, 2016, 19(7):565-566.
[19]
CZOSKI-MURRAY C, CARLTON J, BRAZIER J, et al. Valuing condition-specific health states using simulation contact lenses[J]. Value Health, 2009, 12(5):793-799.
[20]
BALSHAW R F, GONDER J, FERREIRA A, et al. Evaluation of health utility in patients with retinal vein occlusion[J]. Value Health, 2012, 15(7):572.
[21]
BRIGGS A, CLAXTON K, SCULPHER M. Decision Modelling for Health Economic Evaluation[M]. Oxford:Oxford University Press, 2006.
2020, Vol. 55 
